Announcements Trials

Browse Landscape

Phase

Status

Completed 17 Terminated 7 Unknown 2 Withdrawn 1 Recruiting 1 Approved for marketing 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 8 Neoplasms 2 Urinary Bladder Neoplasms 1 Neoplasm Metastasis 1 Advanced Solid Tumors 1

Interventions

Radiosurgery 7 Oxaliplatin 7 Docetaxel 7 Paclitaxel 5 Fluorouracil 5 Nivolumab 4 Magnetic Resonance Spectroscopy 4 Gemcitabine 4 Carboplatin 4 Capecitabine 4 Trastuzumab 3 Radiotherapy 3 Radiation 3 Leucovorin 3 Erlotinib Hydrochloride 3 Cyclophosphamide 3 Cetuximab 3 Bevacizumab 3 spartalizumab 2 sipuleucel-T 2 repotrectinib 2 pembrolizumab 2 pazopanib 2 orteronel 2 fludarabine 2 atezolizumab 2 aldesleukin 2 Temozolomide 2 Surveys and Questionnaires 2 Sunitinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Neoplasm Metastasis × Lapatinib × Clear all

NCT01985893 2016-01-14

THOR

Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡